We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q4 Potential of Tandem Diabetes Care (TNDM): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Tandem Diabetes Care, Inc. (TNDM - Free Report) is expected to reveal quarterly loss of -$0.05 per share, indicating an increase of 88.6% compared to the year-ago period. Analysts forecast revenues of $276 million, representing an increase of 9.3% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.8% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Tandem Diabetes Care metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenue- Supplies and Other' reaching $141.55 million. The estimate suggests a change of +10.4% year over year.
The consensus among analysts is that 'Revenue- Pump' will reach $134.50 million. The estimate indicates a change of +8.3% from the prior-year quarter.
Analysts expect 'Sales- Pump- United States' to come in at $108.34 million. The estimate indicates a year-over-year change of +10.1%.
The combined assessment of analysts suggests that 'Sales- Pump- Outside the United States' will likely reach $26.16 million. The estimate points to a change of +1.5% from the year-ago quarter.
Analysts forecast 'Sales- Supplies and Other- United States' to reach $94.74 million. The estimate indicates a year-over-year change of +10.3%.
The collective assessment of analysts points to an estimated 'Geographic Sales- United States' of $203.09 million. The estimate indicates a year-over-year change of -5.4%.
According to the collective judgment of analysts, 'Sales- Supplies and Other- Outside the United States' should come in at $46.80 million. The estimate indicates a change of +10.6% from the prior-year quarter.
The consensus estimate for 'Geographic Sales- Outside the United States' stands at $72.94 million. The estimate points to a change of -99.9% from the year-ago quarter.
Analysts predict that the 'Pump Shipments - Total Worldwide' will reach 35,032 . Compared to the current estimate, the company reported 34,000 in the same quarter of the previous year.
It is projected by analysts that the 'Pump Shipments - Outside the United States' will reach 9,400 . The estimate compares to the year-ago value of 10,000 .
The average prediction of analysts places 'Pump Shipments - United States' at 25,632 . The estimate compares to the year-ago value of 24,000 .
Over the past month, shares of Tandem Diabetes Care have returned -6% versus the Zacks S&P 500 composite's -1.4% change. Currently, TNDM carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q4 Potential of Tandem Diabetes Care (TNDM): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Tandem Diabetes Care, Inc. (TNDM - Free Report) is expected to reveal quarterly loss of -$0.05 per share, indicating an increase of 88.6% compared to the year-ago period. Analysts forecast revenues of $276 million, representing an increase of 9.3% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.8% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Tandem Diabetes Care metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenue- Supplies and Other' reaching $141.55 million. The estimate suggests a change of +10.4% year over year.
The consensus among analysts is that 'Revenue- Pump' will reach $134.50 million. The estimate indicates a change of +8.3% from the prior-year quarter.
Analysts expect 'Sales- Pump- United States' to come in at $108.34 million. The estimate indicates a year-over-year change of +10.1%.
The combined assessment of analysts suggests that 'Sales- Pump- Outside the United States' will likely reach $26.16 million. The estimate points to a change of +1.5% from the year-ago quarter.
Analysts forecast 'Sales- Supplies and Other- United States' to reach $94.74 million. The estimate indicates a year-over-year change of +10.3%.
The collective assessment of analysts points to an estimated 'Geographic Sales- United States' of $203.09 million. The estimate indicates a year-over-year change of -5.4%.
According to the collective judgment of analysts, 'Sales- Supplies and Other- Outside the United States' should come in at $46.80 million. The estimate indicates a change of +10.6% from the prior-year quarter.
The consensus estimate for 'Geographic Sales- Outside the United States' stands at $72.94 million. The estimate points to a change of -99.9% from the year-ago quarter.
Analysts predict that the 'Pump Shipments - Total Worldwide' will reach 35,032 . Compared to the current estimate, the company reported 34,000 in the same quarter of the previous year.
It is projected by analysts that the 'Pump Shipments - Outside the United States' will reach 9,400 . The estimate compares to the year-ago value of 10,000 .
The average prediction of analysts places 'Pump Shipments - United States' at 25,632 . The estimate compares to the year-ago value of 24,000 .
View all Key Company Metrics for Tandem Diabetes Care here>>>Over the past month, shares of Tandem Diabetes Care have returned -6% versus the Zacks S&P 500 composite's -1.4% change. Currently, TNDM carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .